SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceutical Corporation to Contact Brower Piven Before the January 26, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- NYMX
GlobeNewswire - Mon Dec 22, 7:18PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
NYMX: 0.38 (unch)
Nymox concludes USD1.07m convertible debenture financing
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday the completion of its USD1.07m financing, with Cantone Asset Management as the exclusive agent.
NYMX: 0.38 (unch)
Nymox Announces $1.07 Million Financing
GlobeNewswire - Thu Dec 18, 11:57AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities in the next year. Cantone Asset Management LLC of Tintin Falls NJ served as exclusive agent for the convertible offering.
NYMX: 0.38 (unch)
EQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX
GlobeNewswire - Fri Dec 12, 3:04PM CST
The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.
NYMX: 0.38 (unch)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
GlobeNewswire - Thu Dec 11, 2:09PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
NYMX: 0.38 (unch)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Dec 09, 9:00PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
NYMX: 0.38 (unch)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Dec 08, 8:11AM CST
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
MOLG: 2.92 (+0.03), AVNR: 16.91 (+0.01), HE: 33.35 (+0.17), ADHD: 4.00 (+0.24), NYMX: 0.38 (unch), SDRL: 11.90 (+0.04), SNY: 46.35 (+0.50), AMRI: 15.19 (+0.05), CIE: 8.79 (-0.25)
Escherichia Coli Infections - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtjjhp/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Evolva SA - GangaGen Inc. - Genentech, Inc. - GlycoVaxyn AG - Immuron Limited - Melinta Therapeutics, Inc - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Ltd - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Ltd. - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/dt...ichia_coli
NYMX: 0.38 (unch)
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc.
PR Newswire - Thu Dec 04, 12:21PM CST
Avanir Pharmaceuticals, Inc.
CARB: 14.54 (+0.94), AVNR: 16.91 (+0.01), RLD: 11.35 (+0.02), NYMX: 0.38 (unch), CASY: 89.15 (+0.12), PBYI: 189.96 (+0.12), CODE: 34.55 (+0.64)
Robbins Arroyo LLP: Nymox Pharmaceutical Corporation (NYMX) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Mon Dec 01, 7:07PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Act of 1934 in connection with Nymox's misstatements regarding the viability of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia ("BPH"
NYMX: 0.38 (unch)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Nymox Pharmaceutical Corporation -- NYMX
GlobeNewswire - Wed Nov 26, 6:00PM CST
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey, on behalf of all persons who purchased or otherwise acquired Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
NYMX: 0.38 (unch)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Nymox Pharmaceutical Corporation (NYMX) to Contact the Firm
Marketwired - Wed Nov 26, 3:44PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
NYMX: 0.38 (unch)
Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information
PR Newswire - Wed Nov 26, 1:31PM CST
Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company"
NYMX: 0.38 (unch)
INVESTOR ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Nymox Pharmaceutical Corporation to Recover Investor Losses - NYMX
GlobeNewswire - Tue Nov 25, 1:18PM CST
The Rosen Law Firm announces that a class action lawsuit has been filed on behalf of purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014. The class action seeks to recover investors' losses under the federal securities laws.
NYMX: 0.38 (unch)
Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul Averback by Law Offices Bernard M. Gross, P.C. -- NYMX
GlobeNewswire - Tue Nov 25, 11:38AM CST
Law Offices Bernard M. Gross, P.C. filed a class action lawsuit in the United States District Court, District of New Jersey, 14-cv-07331, on behalf of purchasers of NYMOX common stock between January 31, 2011 and November 2, 2014. This matter is pending before the Honorable Jose L. Linares.
NYMX: 0.38 (unch)
Nymox incurs lower net loss of USD688,206 for Q3 2014
M2 - Mon Nov 17, 6:53AM CST
Diagnostics company Nymox Pharmaceutical (NasdaqCM:NYMX) on Friday declared a net loss of USD688,206 (USD0.02 per share) for the third quarter of 2014.
NYMX: 0.38 (unch)
Nymox Pharma EPS of -$0.02
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:14AM CST
NYMX: 0.38 (unch)
Nymox Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 14, 9:00AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2014. Nymox reported net losses of $688,206, or $0.02 per share, for the quarter and $4,101,293, or $0.12 per share, for the nine months ended September 30, 2014, compared to net losses of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September 30, 2013. The decrease in net losses for the third quarter in 2014 compared to 2013 is mainly due to a reduction of $515,417 in clinical trial expenditures related to NX-1207 studies. The increase in net losses for the nine months ended September 30, 2014 compared to 2013 is mainly due to an increase of stock compensation charges of $1,261,367 relating to the grant of options offset by a decrease of $1,023,460 in clinical trial expenditures.
NYMX: 0.38 (unch)